Navigation Links
New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
Date:11/8/2010

MONDAY, Nov. 8 (HealthDay News) -- Among certain patients with a history of stroke or mini-stroke, a new anticlotting medication called Pradaxa (dabigatran) appears to be as effective as the anticoagulant drug warfarin at preventing a second stroke, new German research reveals.

Specifically, the new study suggests that Pradaxa can reduce the risk of a second stroke as effectively as warfarin among those facing an elevated risk for stroke or arterial blood clot (systemic embolism) as a result of having atrial fibrillation, the most common form of abnormal heart rhythm (or cardiac arrhythmia).

What's more, depending on the dosage used, Pradaxa appeared to fare at least as well or better than warfarin in terms of limiting the risk for bleeding -- a known warfarin side effect.

Pradaxa was recently approved by the U.S. Food and Drug Administration -- at a dosage of 150 milligrams -- for the prevention of first stroke among atrial fibrillation patients.

The current effort took a look at the drug in two twice-daily dosages of either 110 mg or 150 mg among more than 3,600 atrial fibrillation patients, all of whom had previously experienced a stroke or a mini-stroke, also known as a transient ischemic attack.

All of the patients had participated in the larger Randomized Evaluation of Long-Term Anticoagulation Therapy study, which had included more than 18,000 people, 80 percent of whom had no prior history of stroke.

Last year, results of a prior analysis concerning this full study group indicated that at the lower dosage, Pradaxa was as effective at reducing stroke risk as warfarin, while the higher dosage provided even better stroke protection than warfarin.

The new study, published in the Nov. 8 online edition of The Lancet Neurology, was led by Dr. Hans-Christoph Diener from the department of neurology at University Hospital Essen in Essen, Germany.

Diener and his associates focused solely on a smaller subgroup (taken from the larger trial) that had a history of stroke and, therefore, a relatively higher risk for future stroke.

Among such particularly vulnerable patients, the study team found that both dosages of Pradaxa were more or less as effective as warfarin at controlling recurrent stroke risk.

In particular, the lower dosage of Pradaxa (110 mg) was also linked to significant reduction in the rate of vascular death as well as death from all causes, the researchers reported.

However, while major bleeding was also "significantly lower" among the 110-mg Pradaxa group when compared with warfarin patients, the higher dosage of 150 mg of Pradaxa twice daily prompted a bleeding risk that was as high as that found among warfarin patients.

Diener and his colleagues remain unclear as to exactly why the lower dose of Pradaxa prompts a lower rate of bleeding than warfarin, although they speculate that at that dose the drug may not cross the central nervous system's blood-brain barrier, resulting in an improved safety profile.

"In choosing the dose of dabigatran, physicians need to trade off the benefits of stroke prevention against the risk of hemorrhage," the study authors advised in a news release from the publisher.

"In general, strokes are more severe than major hemorrhages and have more significant long-term consequences," Diener's team added. "The dose of 150-mg dabigatran twice daily could be preferred to 110-mg twice daily because it significantly reduces the risk of ischemic stroke without increasing the risk of hemorrhagic stroke."

Meanwhile, the British research team of Dr. Gregory Y.H. Lip and Deirdre A. Lane, both from the University of Birmingham Centre for Cardiovascular Sciences, offered commentary on the new findings in the same issue of the journal. They wrote: "Because of the necessary trade-off between stroke prevention and bleeding with both doses of dabigatran, consultation with patients regarding their preferences for treatment dose will be even more important to ascertain their threshold for stroke prevention over increased bleeding risk or vice versa."

The study was funded by Boehringer-Ingelheim, which makes Pradaxa.

More information

For more on stroke risk, visit the American Heart Association.

-- Alan Mozes

SOURCE: The Lancet Neurology, news release, Nov. 7, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
2. Many Falls, and Resulting ER Visits, Can Be Prevented
3. Asthma drug prevents spread of breast cancer: study
4. Black raspberries may prevent colon cancer, study finds
5. Program May Help Prevent Falls in Hospitalized Patients
6. Pitt study finds NSAIDs cause stem cells to self-destruct, preventing colon cancer
7. Healthy Living Can Prevent Nearly 25% of Colorectal Cancers
8. Chemotherapy plus radiation prevents bladder cancer recurrences
9. Radiation Before Surgery May Prevent Return of Rectal Cancer
10. Wildlife health reporting tools may help prevent human illness
11. UCLA gets $4.6M grant to study HIV treatment, prevention among men from L.A. jails
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
(Date:6/26/2017)... ... ... KICKICO , a protocol built on Ethereum for more transparent ICO ... within funding campaigns. KICKICO developers are testing the platform, which will launch for the ... funds through the power of many - has been around for about ten years ...
(Date:6/25/2017)... ... , ... FCPX LUT Vintage Volume 2 for Final Cut Pro X allows ... 2 contains 60 different color-grade presets, giving editors multiple options for adding different color ... out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for any ...
(Date:6/25/2017)... ... 25, 2017 , ... Republicans in the United States Senate on Thursday released ... Care Reconciliation Act. It differs significantly from the American Health Care Act, which the ... committee, or the House will have to take up the Senate version as-is, if ...
(Date:6/25/2017)... ... , ... CareSet Labs released the Root NPI Graph today at the 2017 ... improved version of the Doctor Referral teaming dataset commonly available from Medicare. , Originally ... the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by ...
(Date:6/25/2017)... ... ... Men’s Health Month and the focus is on prostate cancer. Second only to skin ... third most common cause of cancer related death today; lung cancer remains in the number ... prostate cancer during his lifetime. Those at highest risk are men who have ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... Pa. , June 19, 2017  Researchers from ... today that they will host a live, complimentary webinar ... from the benchtop to the real world" on Wednesday ... EDT. This webinar will feature interviews ... rare look into the manipulation techniques abusers use to ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
Breaking Medicine Technology: